D
대성미생물
036480KOSDAQ의약품 제조업33.5 / 100
Reference Date: 2026-06-10
Financial Score8.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, PER raises overvaluation concerns. Declined 9.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Daesung Microbiological is a specialized animal pharmaceutical company founded in 1966, producing and selling over 150 types of products including vaccines, antibiotics, and nutritional supplements. Its revenue is composed of 72% domestic sales and 28% exports, with a growing export share. The company continuously develops new products through R&D aligned with disease trends.
Number of Employees
138people
Average Salary
44.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
41.40Industry Average 11.930.0Point
3.5x industry avg (risky)
PBR
—Industry Average 0.893.5Point
ROE
1.70Industry Average 4.011.0Point
Well below industry avg
Debt Ratio
39.60Industry Average 12.430.0Point
3.2x industry avg (risky)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲1.1% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲10.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -1.6% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (8%, downtrend)
Current 6,500Won52-week high 9,88052-week low 6,170
1-month return1.0Point
1m -8.96% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
14 totalPositive 0Neutral 14Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-02
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29